Pages that link to "Q33391404"

The following pages link to Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis (Q33391404):

Displaying 38 items.

• Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection (Q24607513) (← links)
• Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? (Q26771601) (← links)
• The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics (Q27010154) (← links)
• Targeting the apoptosis pathway in hematologic malignancies (Q27024422) (← links)
• The Open Form Inducer Approach for Structure-Based Drug Design (Q28554455) (← links)
• Undecylprodigiosin induced apoptosis in P388 cancer cells is associated with its binding to ribosome (Q31120131) (← links)
• A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma (Q33414307) (← links)
• Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy (Q34004454) (← links)
• A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia (Q34294097) (← links)
• Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members (Q34608671) (← links)
• The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment (Q35180339) (← links)
• The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors (Q35975387) (← links)
• Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process (Q36057887) (← links)
• Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer (Q36337960) (← links)
• Mitochondrial permeability transition pore as a selective target for anti-cancer therapy (Q36668047) (← links)
• An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies (Q36696524) (← links)
• GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells (Q36759341) (← links)
• Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation (Q37521403) (← links)
• How to unleash mitochondrial apoptotic blockades to kill cancers? (Q37587294) (← links)
• Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy (Q37589245) (← links)
• Therapeutic approaches in myelofibrosis. (Q37860336) (← links)
• Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms (Q37983083) (← links)
• A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia (Q38061861) (← links)
• Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians (Q38100790) (← links)
• Manipulating the apoptotic pathway: potential therapeutics for cancer patients (Q38115574) (← links)
• Small molecules as pro-apoptotic anticancer agents (Q38162939) (← links)
• Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies? (Q38193997) (← links)
• Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis (Q38567540) (← links)
• Targeting cancer cell mitochondria as a therapeutic approach: recent updates (Q38668524) (← links)
• Cancer and necroptosis: friend or foe? (Q38799139) (← links)
• Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells (Q38999607) (← links)
• Management of myelofibrosis: JAK inhibition and beyond (Q39232415) (← links)
• Structure and Substrate Sequestration in the Pyoluteorin Type II Peptidyl Carrier Protein PltL (Q40718758) (← links)
• BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells (Q41694352) (← links)
• Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia (Q41740316) (← links)
• Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors (Q42061450) (← links)
• Novel Therapies for Myelofibrosis. (Q52817185) (← links)
• Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF (Q90029058) (← links)